When 5-FU chemotherapy reduces this infiltration, cachectic phenotypes are not alleviated, indicating that MDSC cells may not be the primary driver of tumor- and chemotherapy-induced cachexia.318 Similarly, in a preclinical cancer cachexia model, soluble ACVR2B can alleviate the cachectic phenotype by enhancing hepatic protein synthesis and reducing splenomegaly. Here, ACVR2B is linked to neoplasm.